Estimating Aura Biosciences (USA Stocks:AURA) price for December 2023.

Aura Biosciences, Inc. (NASDAQ: AURA), a biotechnology company specializing in the development of therapies for treating cancer, presents a promising investment opportunity. With a strong focus on tumors of high unmet need in ocular and urologic oncology, Aura Biosciences is currently developing AU-011, a virus-like drug conjugates (VDC) candidate for the treatment of primary choroidal melanoma, which is in phase III clinical trial. The company's shares have seen a 52-week high of $14.38, with a current valuation market value of $11.98. Despite an estimated loss of $2.01 per share for the current year and a projected loss of $2.38 for the next year, Aura Biosciences has a strong buy consensus from analysts. The Wall Street target price stands at a robust $27.4, with the highest analyst target price estimated at an impressive $29.33. This bullish outlook is further supported by a naive expected forecast value of $12.49 and a potential upside price of $16.87 by December 2023. With a beta of 0.274, Aura Biosciences presents a relatively low-risk investment opportunity. However, investors should note the company's short ratio of 44.71 and a short percent of 0.088, indicating a significant number of shares shorted in the prior month (2.7M). As we approach December 2023, Aura Biosciences could offer substantial returns for investors willing to weather the current losses. The company's innovative approach to cancer treatment and strong analyst consensus make it a stock to watch in the biotechnology sector. Currently, Aura Biosciences' Invested Capital is projected to see a significant increase, based on the reporting trends of the past few years. The Book Value per Share for the current year is expected to rise to 7.05, while the Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) are predicted to decline to ($62.1 million). The purpose of this article is to forecast the future value of Aura Biosciences using technical analysis. So, what should investors in Aura Biosciences anticipate in December?
Published over three months ago
View all stories for Aura Biosciences | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Gabriel Shpitalnik

Aura Biosciences has a beta of 3.2728. This suggests that as market returns increase, Aura Biosciences' returns are expected to increase more than the market, not less. Conversely, during a bear market, the potential loss from holding Aura Biosciences is expected to be larger. The beta indicator assists investors in understanding whether Aura Biosciences moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is relative to the market (i.e., selected benchmark). In other words, if Aura Biosciences deviates significantly from the market, it adds more risk to the portfolio, but it also increases the potential for higher returns.

Important Points

Investing in Aura Biosciences (USA Stocks: AURA) presents a promising opportunity, with a potential upside of 9.24% by December 2023. The biotechnology company, known for its innovative approach in treating high-need tumors in ocular and urologic oncology, has shown resilience with a 52-week high of $14.38 and a low price of $10.49. The company's beta of 0.274 indicates lower volatility compared to the market, making it a potentially safer investment in the biotech industry. Aura's Mean Deviation of 2.88 and Coefficient of Variation of 2.2K further underscore its stability, suggesting less risk associated with the stock. However, investors should note the company's high Short Ratio of 44.71, indicating a significant number of shorted shares at 2.7M. This could potentially lead to a short squeeze, driving the stock price higher in the short term. Despite the potential downside risk of 5.96, Aura Biosciences' promising pipeline and steady performance make it an attractive investment opportunity.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Aura Biosciences. Regardless of method or technology, to accurately forecast the stock or bond market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Aura Biosciences

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Aura Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Aura Biosciences in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Aura Biosciences. Your research has to be compared to or analyzed against Aura Biosciences' peers to derive any actionable benefits. When done correctly, Aura Biosciences' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Aura Biosciences.

How important is Aura Biosciences's Liquidity

Aura Biosciences financial leverage refers to using borrowed capital as a funding source to finance Aura Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Aura Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Aura Biosciences' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Aura Biosciences' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Aura Biosciences's total debt and its cash.

A Deeper Perspective

The modest gains experienced by current holders of Aura Biosciences could raise concerns from investors as the firm is trading at a share price of 11.98 on very low momentum in volume. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in October. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.38. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Aura Biosciences partners.

Returns Breakdown

Return on Assets(0.39)
Return on Equity(0.44)
Return Capital(0.8)
Every cloud has a silver lining, and Aura Biosciences (USA Stocks:AURA) seems to be on the verge of revealing its own. Despite a challenging year marked by a 52-week low of $6.6, Aura Biosciences, a biotechnology company focusing on cancer therapies, has shown promise with its virus-like drug conjugates technology platform.
The company's substantial working capital of $186.25M and robust current ratio of 21.97X highlight its financial health. Moreover, Wall Street's target price for the stock stands at an encouraging $27.4, indicating a potential upside of 9.24%. The firm's risk-adjusted performance at 0.0388 and market risk-adjusted performance at 0.0672 further underscore its resilience amidst market fluctuations. However, investors should be aware of Aura's probability of bankruptcy at 24.73%. With a market capitalization of $457.6M, Aura Biosciences represents a promising investment opportunity, anticipated to realize significant gains by December 2023. .

Our perspective of the current Aura Biosciences rise

The current total risk alpha for Aura Biosciences, which stands at 0.57, offers an intriguing perspective on the company's recent growth. This metric measures the return on investment while taking into account systematic risk, suggesting that Aura Biosciences is delivering a better-than-expected return given the level of risk involved. This positive risk-return trade-off is a strong indicator of the company's robust financial health and strategic direction, making it an appealing prospect for investors looking to capitalize on its upward trajectory. As of November 6th, Aura Biosciences displays a Mean Deviation of 2.88, a risk-adjusted performance of 0.0388, and a Downside Deviation of 3.84. Aura Biosciences' technical analysis provides a methodology to utilize historical prices and volume patterns to determine a pattern that approximates the direction of the company's future prices. In other words, this information can be used to ascertain whether the company will indeed mirror its model of historical prices and volume momentum, or if the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Aura Biosciences, which can be compared to its competitors. Please verify Aura Biosciences' value at risk, and the relationship between the Jensen Alpha and Semi Variance to determine if Aura Biosciences is priced correctly, assuming the market reflects its regular price of 11.98 per share.
Given that Aura Biosciences has a Jensen Alpha of 0.378, we recommend you to validate Aura Biosciences's current market performance to ensure the company can sustain itself in the future. In light of the recent price surge of Aura Biosciences, Inc. (USA Stocks:AURA), a careful analysis of the company's valuation metrics suggests that the current price may not be entirely justified. The company's Valuation Real Value stands at 16.02, significantly lower than the Analyst Target Price Estimated Value of 29.333. This discrepancy indicates a potential overvaluation of the stock. Moreover, the Naive Expected Forecast Value is only 12.49, further suggesting that the current price might be inflated. Despite the Analyst Overall Consensus being a 'Strong Buy', with 5 strong buy recommendations, the Posible Downside Price is 8.11, which could indicate a potential risk for investors. Therefore, while Aura Biosciences' work in developing therapies for high-need cancer treatments is commendable, investors should exercise caution and thoroughly evaluate the company's financials before making investment decisions. .

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Aura Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com